Turkish Thoracic Journal
Oral Presentation

Can Serum Lactate Dehydrogenase Level be Used for Predicted to IPF Clinical Severity?

1.

Clinic of Chest Diseases, University of Health Sciences, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey

Turk Thorac J 2019; 20: Supplement 158-158
DOI: 10.5152/TurkThoracJ.2019.158
Read: 459 Downloads: 210 Published: 01 August 2019

Objectives: Serum lactate dehydrogenase (LDH) is a marker of cell damage and may be reflect pulmonary fibrosis. In a recent studies represented LDH level may related to pathogenesis and prognosis of idiopathic pulmonary fibrosis (IPF). We aimed to investigated relationship between serum LDH level and IPF severity.
 

Methods: We retrospectively evaluated 42 patients (female/male 9/28) with IPF. The demographic parameters, pulmonary function tests, diffusion test, 6-minutes walk test and IPF stage were recorded.
 

Results: The mean age of the patients was 66.9±6.0 (range 53-78) years with 33 (78.6%) men. Among our cohort 31 (73.8%) were current or ex-smokers with a mean exposure of cigarette 37.5 pack-years. The mean GAP point was 4.2±1.4. The most common IPF stage was 2 (25 59.5%) and mean serum LDH level was 255.5±43.2 U/L (range 161-332). In our laboratory the cut of serum LDH level was 247 U/L. Serum LDH was increased in 26 (61.9%) of IPF patients. In patients with higher serum LDH level had higher GAP score (4.6±1.3 vs 3.6±1.2 p=0.020), lower FVC % predicted (62.8±15.8 vs 77.9±16.8, p=0.006) and FEV1 % predicted (67.8±16.9 vs 80.31±14.4 p=0.019) than normal LDH group. There was no significant differences between serum LDH level and age, gender, GAP score, DLCO, FEV1/FVC ratio.
 

Conclusion: In IPF patients increased serum activity of serum LDH may represent a marker of IPF stage. Future research is needed to determine the serum LDH level importance in IPF patients.

Files
EISSN 2149-2530